The ITGB3 gene gives instructions for part of a protein on platelets, the blood cells that clump together to help stop bleeding. If this gene does not work properly, platelets may not stick together as they should, which can lead to easy bruising, nosebleeds, or heavier bleeding after injury or surgery. This gene also helps some cells attach to their surroundings and send signals that support normal tissue and blood vessel function. Some variants in the ITGB3 gene are linked to Glanzmann thrombasthenia, an inherited bleeding condition.
What is a gene?
Genes are stretches of DNA that give your cells instructions to make molecules or manage processes in the body. Some genes carry the code for proteins, which do much of the cell’s work. Others mainly regulate when certain activities happen, where they take place, and how active they are. Together, genes affect how the body develops and functions, and they can also influence how you respond to food, stress, or medications. For a more detailed look at this topic, you can learn more in the LearnHub.
Overview
ITGB3Gene function
What if the gene works
The ITGB3 gene makes part of a surface protein on platelets and some other cells. It helps platelets clump to form blood clots and supports cell attachment, movement, and signaling.
Risk
What if the gene does not work
Pathogenic variants in the ITGB3 gene most often cause Glanzmann thrombasthenia, a platelet condition with easy bruising, nosebleeds, and heavier bleeding after injuries or procedures. Milder or more severe variants can change when bleeding starts and how strong it is.
Treatment
What does that mean for your treatment
For people with a pathogenic variant in the ITGB3 gene, treatment planning often centers on bleeding control. Platelet transfusions may be used for major bleeding or surgery, and recombinant factor VIIa can help, especially if platelet refractoriness or antibodies develop. Medicines that raise bleeding risk, such as aspirin and many NSAIDs, are usually avoided.
Conditions associated with ITGB3
Gene function
What if the gene works
For blood clotting and cell attachment, your body relies on the ITGB3 gene. It helps make part of a surface receptor that lets platelets and some other cells grip, sense, and respond to their surroundings. This supports normal platelet function and steady cell communication.
In platelets, the ITGB3 gene helps build a surface receptor that binds clotting proteins after a blood vessel is injured. This lets platelets stick to one another, which is a key step in normal blood clotting.
Signals through this receptor help platelets spread out and pull on the forming clot. That makes the platelet plug more compact and stable as bleeding is brought under control.
In some other cells, ITGB3-containing receptors help the cell attach to proteins in the tissue around it. This grip supports steady contact with the body’s support scaffold and nearby cells.
When these surface receptors attach, they also send messages into the cell. These messages help guide cell shape, movement, and everyday responses to the surrounding environment.
What is a variant?
A genetic variant is a small alteration in the DNA sequence of a gene. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, and how the body responds to environmental influences. Many variants do not have any noticeable effect and simply represent natural genetic variation. In some situations, though, a variant can more substantially change how a gene functions and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the ITGB3 gene can change how the β3 protein folds, reaches the platelet surface, binds, or sends signals. When looking at how ITGB3 gene variants affect platelet function, there is a spectrum: milder variants may leave partial receptor activity, while more severe variants can abolish it. This often helps explain why Glanzmann thrombasthenia can vary in how early bleeding appears and how marked it is.
How variants are linked to conditions
Pathogenic variants in the ITGB3 gene can cause Glanzmann thrombasthenia, an inherited bleeding condition with easy bruising, nosebleeds, gum bleeding, and longer bleeding after injury or surgery. In this setting, the link between the ITGB3 gene and Glanzmann thrombasthenia is well established, and a confirmed pathogenic variant can support or confirm the diagnosis. Some ITGB3 changes also define platelet antigen types that matter in fetal and neonatal alloimmune thrombocytopenia and in platelet transfusion matching.
A variant is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are widely seen across the general population. Most do not have a direct effect on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition indicates a possible link rather than a certain diagnosis, especially when more than one gene and environmental influences are involved. In some cases, though, a single well understood variant in a specific gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For inherited bleeding problems linked to ITGB3, risk is mainly set by the genetic change itself rather than by lifestyle. Bleeding can be worse with aspirin, ibuprofen, and other medicines that affect platelets, and injuries or surgery can also raise the chance of bleeding.
Inheritance of ITGB3 variants
The inheritance pattern for ITGB3-related conditions depends on the specific variant and condition involved. Most often, variants in the ITGB3 gene linked to Glanzmann thrombasthenia are inherited in an autosomal recessive pattern, which means a child inherits one nonworking copy from each parent. Parents who each carry one variant are usually unaffected, and with each pregnancy there is a 25% chance the child will inherit both variants. In some families, other ITGB3 gene changes are inherited in an autosomal dominant pattern, so one altered copy can be enough to affect platelet count or function. This is the key point when asking how variants of the ITGB3 gene are inherited.
What does my ITGB3 result mean for my family?
ITGB3 results can mean different things for family members, depending on the specific change and condition involved. Most often, ITGB3 is linked to an inherited bleeding condition where parents may be healthy carriers, and brothers, sisters, or future children could also carry the change or be affected. Some rarer ITGB3 changes follow a dominant pattern, which means close relatives may also have the variant.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the ITGB3 gene, clinicians use genetic testing for ITGB3 variants on a blood, saliva, or cheek swab sample. A lab reads the gene’s DNA code and compares it with the usual sequence to identify changes that may help explain a diagnosed platelet condition or carrier status.
When should I consider getting a genetic test?
Genetic testing for the ITGB3 gene can be worth considering if someone has lifelong easy bruising, frequent nosebleeds, heavy periods, or unusual bleeding after dental work or surgery, especially when tests suggest a rare inherited platelet bleeding condition called Glanzmann thrombasthenia. It can also help when this condition runs in the family or when both parents are known carriers.
A genetic result is only one part of your health story
A genetic result may provide meaningful information, but how much it explains depends on both the condition and the type of variant. Many factors, including lifestyle, environment, age, and medical history, influence how the body works over time. In some conditions, especially those shaped by many genes, genetic information provides context rather than certainty and is most useful when considered alongside other parts of care. In other situations, a genetic result can offer a clear answer. In areas such as medication response, genetic results can help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in DNA can change how the body breaks down a drug, moves it through the body, or how strongly the drug target responds. This helps explain why the same treatment may work well for one person, seem less effective for another, or cause more side effects in someone else. These differences are common and are one part of the bigger picture alongside age, other health conditions, and other medicines.
What is Pharmacogenetics?
Pharmacogenetics focuses on how genetic variation can shape a person’s response to medication. By examining the relationship between genes and drugs, it helps explain why the same treatment can work differently from one person to another. For many medicines, genes can affect both how strongly a drug works and how the body handles it. This understanding can support treatment decisions that are more informed and more individualized. You can read more about this topic in the LearnHub.
Drugs influenced by the ITGB3 gene
When should I seek medical advice?
There isn't yet a broadly confirmed role for this gene in guiding medication choice or dose, so questions about medicines or side effects are best discussed with your doctor. Research on the ITGB3 gene has looked at whether some gene changes may affect how platelets, the blood cells that help clot, respond to medicines like aspirin, but this is not used routinely in care.
History
Across cultures and time periods, inherited bleeding patterns were noted long before the cause was clear. In the 20th century, doctors studying people with Glanzmann thrombasthenia linked the condition to missing or altered platelet surface proteins, first known as glycoproteins IIb and IIIa. From these first observations, research expanded steadily. Scientists later showed that glycoprotein IIIa is produced by the ITGB3 gene, and cloning the gene helped connect rare inherited bleeding conditions with a precise genetic cause. This work also shaped modern platelet medicine, because the αIIbβ3 receptor became a major target for drugs used during some heart procedures. Over time, the ITGB3 gene became part of the broader story of how blood clotting, inherited risk, and targeted treatment came to be understood.